Article: The American Journal of Psychiatry Publishes Data on Clinical Trial of Nalmefene in the Treatment of Pathological Gambling.

SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- Somaxon Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of psychiatric and neurological disorders, today said that the February 2006 issue of the American Journal of Psychiatry features an article which describes the conduct and results of a four-month clinical trial investigating the efficacy and safety of one of its product candidates, oral nalmefene hydrochloride, an opioid antagonist, in reducing pathological gambling-related urges, thoughts and behaviors.

BioTie Therapies Corp. of Finland sponsored the trial, which was completed ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!